Screener
NovoCure NVCR Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by NovoCure in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: NovoCure’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 6:59 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001645113-26-000062
| Line item | June 30,2026 | December 31, 2025 |
|---|---|---|
| SHAREHOLDERS' EQUITY: | ||
| Share capital - | ||
| Ordinary shares no par value, Unlimited shares authorized; issued and outstanding:116,442,465 shares and 112,492,667 shares at June 30, 2026 (unaudited) and December 31, 2025, respectively | — | — |
| Additional paid-in capital | 1,718,667 | 1,634,264 |
| Accumulated other comprehensive income (loss) | (3,422) | (3,441) |
| Retained earnings (accumulated deficit) | (1,377,153) | (1,290,357) |
| TOTAL SHAREHOLDERS' EQUITY | 338,092 | 340,466 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $795,191 | $804,326 |
Item 1. Financial Statements
FAQ
- What is NovoCure's total equity?
- NovoCure (NVCR) reported total equity of $338.09M in Q2 2026.
- How has NovoCure's total equity changed year-over-year?
- NovoCure's total equity decreased by 3.2% year-over-year, from $349.44M to $338.09M.
- What is the long-term trend for NovoCure's total equity?
- Over 5 years (2020 to 2025), NovoCure's total equity has grown at a -6.5% compound annual growth rate (CAGR), from $476.53M to $340.47M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about NovoCure's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude